Next-generation yellow fever vaccine shows comparable efficacy to standard vaccine

1. A next-generation live-attenuated yellow fever vaccine (vYF) demonstrated noninferior immunogenicity compared to the standard vaccine, with nearly universal seroconversion by one month after vaccination.

2. Safety profiles were similar between groups, with no vaccine-related serious adverse events observed over one year of follow-up.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Yellow fever remains a major global health threat, particularly in endemic regions of Africa and South America, where outbreaks continue to cause substantial mortality and strain vaccine supply chains. Existing vaccines are highly effective, but shortages during outbreaks have highlighted the need for scalable alternatives. This randomized controlled trial evaluated a next-generation vaccine (vYF) designed to improve manufacturing capacity while maintaining efficacy. The study found that vYF elicited an immune response comparable to the currently licensed vaccine, with nearly all participants achieving protective antibody levels within the first month. These responses persisted through one year, suggesting durable immunity. Importantly, the safety profile of vYF closely mirrored that of the standard vaccine, with mostly mild, transient adverse effects and no major safety concerns identified. Strengths of the study included its randomized, observer-blinded design and its use of an active comparator which enhanced internal validity. One limitation was the restriction of enrollment to healthy adults in a non-endemic setting, which may limit generalizability to higher-risk populations such as children, older adults, or immunocompromised individuals. Additionally, the study was not powered to detect rare adverse events, and follow-up remains ongoing for long-term durability. Nonetheless, this study suggests promising early efficacy and safety of a next-generation live-attenuated yellow fever vaccine.

Click to read the study in NEJM

Relevant Reading: Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models

In-Depth [randomized controlled trial]: This phase 2, observer-blinded randomized controlled trial evaluated the immunogenicity and safety of a next-generation live-attenuated yellow fever vaccine (vYF) compared with the licensed vaccine (YF-VAX). A total of 568 healthy adults aged 18 to 60 years were enrolled across 11 centers in the United States and randomized in a 2:1 ratio to receive a single dose of vYF or YF-VAX. The primary endpoint was seroconversion at day 29 among participants with no prior yellow fever infection or vaccination in the per-protocol population. Seroconversion occurred in 328 of 329 participants (99.7%) in the vYF group and 155 of 156 participants (99.4%) in the YF-VAX group, yielding a between-group difference of 0.3 percentage points (95% confidence interval [CI], -1.2 to 3.2). Neutralizing antibody geometric mean titers rose substantially by day 29 in both groups, peaking at approximately 1:2654 for vYF and 1:3147 for YF-VAX in participants without prior exposure and remaining above the protective threshold (≥1:10) in more than 97% of both groups at 1 year.  In a subgroup evaluated at day 11, protective titers were observed in a smaller percentage of vYF recipients versus YF-VAX recipients (38% versus 61%); however, the study was not powered to assess noninferiority at this early time point. Solicited adverse events occurred in 56.7% of participants receiving vYF and 61.1% receiving YF-VAX, most commonly headache (36.5% vs. 37.8%) and injection-site pain (28.7% vs. 31.4%). Serious adverse events were rare and not considered related to vaccination. These findings demonstrate acceptable early efficacy and safety of a next-generation yellow fever vaccine.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.